A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in walker carcinoma cells-Reference-Cited by-同舟云学术

A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in walker carcinoma cells

Published:1988-12 Issue:24 Volume:37 Page:4661-4669
ISSN:0006-2952
Container-title:Biochemical Pharmacology
language:en
Short-container-title:Biochemical Pharmacology

Author:

Knox Richard J.,Friedlos Frank,Jarman Michael,Roberts John J.

Publisher

Elsevier BV

Subject

Pharmacology,Biochemistry

Reference29 articles.

1. 2,4-Dinitro-5-ethy-leneiminobenzamide (CB 1954): a potent and selective inhibitor of growth of the Walker carcinoma 256;Cobb;Biochem Pharmacol,1969

2. CB 1954 (2,4-dinitro-5-aziridinyl benzamide) becomes a DNA interstrand crosslinking agent in Walker tumour cells;Roberts;Biochem Biophys Res Commun,1986

3. CB 1954 Revisited I. Disposition kinetics and metabolism;Workman;Cancer Chemother Pharmacol,1986

4. CB 1954 Revisited II. Toxicity and antitumour activity;Workman;Cancer Chemother Pharmac,1986

5. Studies on the reversal of the selective antitumour effect of the aziridinyl derivative CB 1954 by 4-amino-5-imidazolecarboxamide;Connors;Int J Cancer,1972

Cited by 167 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Smart nanocarriers for enzyme-activated prodrug therapy;Journal of Drug Targeting;2024-07-26

2. Bacteria-Based Approach to Cancer Therapy;Interdisciplinary Cancer Research;2024

3. The Crystal Structure of Engineered Nitroreductase NTR 2.0 and Impact of F70A and F108Y Substitutions on Substrate Specificity;International Journal of Molecular Sciences;2023-04-01

4. The dinitrobenzamide mustard prodrugs, PR-104A and SN27686, for use in a novel MNDEPT cancer prodrug therapy approach;Bioscience Reports;2023-04

5. Drug targeting in anticancer chemotherapy;Medicinal Chemistry of Anticancer Drugs;2023